Literature DB >> 31133599

Lactate jump-starts mTORC1 in cancer cells.

Don Benjamin1, Michael N Hall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31133599      PMCID： PMC6549024          DOI： 10.15252/embr.201948302

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  9 in total

1.  Monocarboxylate transporter MCT1 is a target for immunosuppression.

Authors:  Clare M Murray; Raymond Hutchinson; John R Bantick; Graham P Belfield; Amanda D Benjamin; Diana Brazma; Robert V Bundick; I David Cook; Robert I Craggs; Susan Edwards; Leslie R Evans; Richard Harrison; Elain Holness; Andrew P Jackson; Clive G Jackson; Lee P Kingston; Matthew W D Perry; Andrew R J Ross; Paul A Rugman; Sasvinder S Sidhu; Michael Sullivan; David A Taylor-Fishwick; P Craig Walker; Yvonne M Whitehead; David J Wilkinson; Andrew Wright; David K Donald
Journal:  Nat Chem Biol       Date:  2005-12       Impact factor: 15.040

Review 2.  An overview of MCT1 and MCT4 in GBM: small molecule transporters with large implications.

Authors:  Simon J Park; Chase P Smith; Ryan R Wilbur; Charles P Cain; Sankeerth R Kallu; Srijan Valasapalli; Arpit Sahoo; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

3.  Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.

Authors:  C J Kuo; J Chung; D F Fiorentino; W M Flanagan; J Blenis; G R Crabtree
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Oncogenic KRAS signaling activates mTORC1 through COUP-TFII-mediated lactate production.

Authors:  Jun-Kyu Byun; Mihyang Park; Jae Won Yun; Jaebon Lee; Jae Sun Kim; Sung Jin Cho; You Mie Lee; In-Kyu Lee; Yeon-Kyung Choi; Keun-Gyu Park
Journal:  EMBO Rep       Date:  2019-04-15       Impact factor: 8.807

5.  Lactate Metabolism in Human Lung Tumors.

Authors:  Brandon Faubert; Kevin Y Li; Ling Cai; Christopher T Hensley; Jiyeon Kim; Lauren G Zacharias; Chendong Yang; Quyen N Do; Sarah Doucette; Daniel Burguete; Hong Li; Giselle Huet; Qing Yuan; Trevor Wigal; Yasmeen Butt; Min Ni; Jose Torrealba; Dwight Oliver; Robert E Lenkinski; Craig R Malloy; Jason W Wachsmann; Jamey D Young; Kemp Kernstine; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

Review 6.  Lactic Acid: No Longer an Inert and End-Product of Glycolysis.

Authors:  Shiren Sun; Heng Li; Jianghua Chen; Qi Qian
Journal:  Physiology (Bethesda)       Date:  2017-11

Review 7.  Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses.

Authors:  Alexandre Morrot; Leonardo Marques da Fonseca; Eduardo J Salustiano; Luciana Boffoni Gentile; Luciana Conde; Alessandra Almeida Filardy; Tatiany Nunes Franklim; Kelli Monteiro da Costa; Celio Geraldo Freire-de-Lima; Leonardo Freire-de-Lima
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

8.  Lactate administration activates the ERK1/2, mTORC1, and AMPK pathways differentially according to skeletal muscle type in mouse.

Authors:  Hugo Cerda-Kohler; Carlos Henríquez-Olguín; Mariana Casas; Thomas E Jensen; Paola Llanos; Enrique Jaimovich
Journal:  Physiol Rep       Date:  2018-09

9.  GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy.

Authors:  Ji Hye Im; Keon Wook Kang; Sun Young Kim; Yoon Gyoon Kim; Yong Jin An; Sunghyouk Park; Byung Hwa Jeong; Song-Yi Choi; Jin-Sun Lee; Keon Wook Kang
Journal:  J Exp Clin Cancer Res       Date:  2018-11-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.